CA3026142C - Crystalline form of compound suppressing protein kinase activity, and application thereof - Google Patents

Crystalline form of compound suppressing protein kinase activity, and application thereof Download PDF

Info

Publication number
CA3026142C
CA3026142C CA3026142A CA3026142A CA3026142C CA 3026142 C CA3026142 C CA 3026142C CA 3026142 A CA3026142 A CA 3026142A CA 3026142 A CA3026142 A CA 3026142A CA 3026142 C CA3026142 C CA 3026142C
Authority
CA
Canada
Prior art keywords
crystalline form
disease
compound
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3026142A
Other languages
English (en)
French (fr)
Other versions
CA3026142A1 (en
Inventor
Congxin Liang
Yongbin MA
Wei He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xcovery Holdings Inc
Original Assignee
Xcovery Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcovery Holdings Inc filed Critical Xcovery Holdings Inc
Publication of CA3026142A1 publication Critical patent/CA3026142A1/en
Application granted granted Critical
Publication of CA3026142C publication Critical patent/CA3026142C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3026142A 2016-06-01 2017-06-01 Crystalline form of compound suppressing protein kinase activity, and application thereof Active CA3026142C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/084300 2016-06-01
CNPCT/CN2016/084300 2016-06-01
PCT/CN2017/086760 WO2017206924A1 (zh) 2016-06-01 2017-06-01 抑制蛋白激酶活性化合物的晶型及其应用

Publications (2)

Publication Number Publication Date
CA3026142A1 CA3026142A1 (en) 2017-12-07
CA3026142C true CA3026142C (en) 2024-02-13

Family

ID=60477983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026142A Active CA3026142C (en) 2016-06-01 2017-06-01 Crystalline form of compound suppressing protein kinase activity, and application thereof

Country Status (17)

Country Link
US (1) US10899744B2 (cg-RX-API-DMAC7.html)
EP (1) EP3470410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7054528B2 (cg-RX-API-DMAC7.html)
KR (1) KR102466958B1 (cg-RX-API-DMAC7.html)
CN (1) CN109195964B (cg-RX-API-DMAC7.html)
AU (1) AU2017274110B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026142C (cg-RX-API-DMAC7.html)
EA (1) EA201892687A1 (cg-RX-API-DMAC7.html)
ES (1) ES2981015T3 (cg-RX-API-DMAC7.html)
IL (1) IL263356B (cg-RX-API-DMAC7.html)
MY (1) MY188379A (cg-RX-API-DMAC7.html)
PH (1) PH12018502529A1 (cg-RX-API-DMAC7.html)
PL (1) PL3470410T3 (cg-RX-API-DMAC7.html)
RU (1) RU2744264C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201810800VA (cg-RX-API-DMAC7.html)
TW (1) TWI646094B (cg-RX-API-DMAC7.html)
WO (1) WO2017206924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279579B2 (en) 2018-06-21 2023-02-01 Betta Pharmaceuticals Co Ltd Crystalline form of a compound to inhibit the activity of cdk4/6 and its use
WO2022031636A1 (en) 2020-08-03 2022-02-10 Teva Pharmaceuticals International Gmbh Solid state forms of ensartinib and ensartinib salts
CN117897156A (zh) * 2021-08-10 2024-04-16 贝达药业股份有限公司 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
KR102851417B1 (ko) * 2022-08-16 2025-08-28 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제
CN118021811A (zh) * 2023-12-28 2024-05-14 复旦大学附属华山医院 一种靶向于csf1r激酶的6-氟吡啶甲酰苯胺类抑制剂、药物组合物及其核素成像试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1963302E (pt) 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
CN101652068A (zh) * 2007-01-19 2010-02-17 艾科睿制药公司 激酶抑制物化合物
KR101691640B1 (ko) * 2008-06-19 2016-12-30 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
EA025030B1 (ru) * 2010-10-08 2016-11-30 Икскавери Холдинг Кампани, Ллс Соединение {5-[(1r)-1-(2,6-дихлор-3-фторфенил)этокси]-6-аминопиридазин-3-ил}-n-(1-метил-6-оксо-1,6-дигидропиридин-3-ил)карбоксамид в качестве киназного ингибитора
EP2625176B1 (en) * 2010-10-08 2016-08-17 Xcovery Holding Company LLC Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Also Published As

Publication number Publication date
KR20190012231A (ko) 2019-02-08
WO2017206924A1 (zh) 2017-12-07
US20190135792A1 (en) 2019-05-09
HK1259249A1 (zh) 2019-11-29
EA201892687A1 (ru) 2019-06-28
TWI646094B (zh) 2019-01-01
SG11201810800VA (en) 2019-01-30
RU2744264C2 (ru) 2021-03-04
AU2017274110A1 (en) 2019-01-24
US10899744B2 (en) 2021-01-26
PL3470410T3 (pl) 2024-09-16
JP2019518026A (ja) 2019-06-27
ES2981015T3 (es) 2024-10-04
AU2017274110B2 (en) 2021-05-06
NZ788961A (en) 2024-12-20
NZ750921A (en) 2024-12-20
IL263356B (en) 2022-08-01
CA3026142A1 (en) 2017-12-07
RU2018145183A3 (cg-RX-API-DMAC7.html) 2020-07-16
EP3470410A4 (en) 2019-12-04
TW201742865A (zh) 2017-12-16
CN109195964B (zh) 2021-08-10
EP3470410B1 (en) 2024-04-17
RU2018145183A (ru) 2020-07-14
PH12018502529A1 (en) 2019-04-08
EP3470410A1 (en) 2019-04-17
CN109195964A (zh) 2019-01-11
IL263356A (en) 2018-12-31
BR112018074612A2 (pt) 2019-03-19
JP7054528B2 (ja) 2022-04-14
MY188379A (en) 2021-12-07
KR102466958B1 (ko) 2022-11-14

Similar Documents

Publication Publication Date Title
EP3292115B1 (en) Crystalline form of fused pyridine derivative's maleate and uses thereof
AU2017274110B2 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
JP2020007327A (ja) 癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
CN106146583B (zh) 新型胞苷衍生物及其应用
CN117866030A (zh) 用于治疗癌症的环状二核苷酸化合物
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
TW202411219A (zh) 雜環化合物ccr4抑制劑及其用途
CN105705494B (zh) 喹唑啉衍生物及其药物组合物,以及作为药物的用途
CN104341434B (zh) 取代的雷帕霉素三氮唑衍生物和用途
CN103373986B (zh) 克里唑替尼前药及其制备方法与用途
JP7755347B2 (ja) 腎癌の標的治療のための新規化合物及び組成物
AU2022275275A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
WO2016078397A1 (zh) 新型胞苷衍生物及其应用
EA041596B1 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
HK1259249B (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
BR112018074612B1 (pt) Compostos intermediários, composto que suprime a atividade de proteína quinase, sua forma cristalina, método de produção, composição farmacêutica e aplicação da forma cristalina
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途
KR20130141469A (ko) 피라졸릴아미노퀴나졸린의 브롬화수소 염

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220317

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250521

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260526